We’ve joined the Health Research Authority, the National Institute for Health and Care Research, and a host of organisations ...

It recommends healthcare practitioners should offer a low-dose combination of inhaled corticosteroids (ICS) and formoterol to be taken as needed for everyone aged 12 and over with newly diagnosed ...

These sections briefly explain why the committee made the recommendations and how they might affect practice. As this guideline applies to England and Scotland, the perspective was for both England ...

There is a simple discount patient access scheme for eplontersen. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact Market.AccessUK ...

This indicator covers the percentage of patients with cardiovascular disease in whom the last recorded LDL or non-HDL cholesterol level (measured in the preceding 12 months) is 2.0 mmol per litre or ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Associate professor and director of the Medical Technology Research Group, London School of Economics and Political Science (LSE) The rapidly evolving healthcare landscape demands leaders who can ...

To find BTS, NICE or SIGN guidance on related topics, including guidance in development, see the BTS guidelines, the NICE topic page on asthma and the SIGN guidelines. For full details of the evidence ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

We will update the guideline on asthma.